haloperidol lactate - Profile

What are the generic drug sources for haloperidol lactate and what is the scope of freedom to operate?

Haloperidol lactate is the generic ingredient in four branded drugs marketed by Ortho Mcneil, Alpharma, Lannett Co Inc, Morton Grove, Pharm Assoc, Rubicon Research, SCS, Teva, Teva Pharms, Hikma, Janssen Pharms, Abraxis Pharm, Baxter Hlthcare Corp, Epic Pharma Llc, Fosun Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Marsam Pharms Llc, Mylan Labs Ltd, Sagent Pharms, Smith And Nephew, Solopak, Teva Pharms Usa, Watson Labs, and Actavis Mid Atlantic, and is included in thirty-four NDAs. Additional information is available in the individual branded drug profile pages.

Summary for haloperidol lactate

US Patents:	0
Tradenames:	4
Applicants:	25
NDAs:	34

US Patents and Regulatory Information for haloperidol lactate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ortho Mcneil	HALDOL	haloperidol lactate	CONCENTRATE;ORAL	015922-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Alpharma	HALOPERIDOL	haloperidol lactate	CONCENTRATE;ORAL	070318-001	Apr 11, 1986		DISCN	No	No
Lannett Co Inc	HALOPERIDOL	haloperidol lactate	CONCENTRATE;ORAL	073364-001	Sep 28, 1993	AA	RX	No	No
Morton Grove	HALOPERIDOL	haloperidol lactate	CONCENTRATE;ORAL	070710-001	Mar 7, 1986		DISCN	No	No

Expired US Patents for haloperidol lactate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ortho Mcneil	HALDOL	haloperidol lactate	CONCENTRATE;ORAL	015922-001	Approved Prior to Jan 1, 1982
Janssen Pharms	HALDOL	haloperidol lactate	INJECTABLE;INJECTION	015923-001	Approved Prior to Jan 1, 1982

Haloperidol Lactate: Investment & Fundamentals Analysis

Last updated: February 19, 2026

Haloperidol lactate is an established antipsychotic medication with a significant market presence, primarily serving acute agitation and psychosis management. Its investment profile is characterized by mature product status, generic competition, and a stable demand driven by its therapeutic role. Patent expirations and the absence of new molecular entity status limit novel market expansion opportunities.

What is the Market Landscape for Haloperidol Lactate?

The market for haloperidol lactate is mature and largely driven by its use in inpatient psychiatric settings and emergency departments for the rapid control of agitation and psychosis. Generic manufacturers dominate this space, resulting in a price-sensitive market. Key therapeutic areas include schizophrenia, bipolar disorder, and delirium.

Market Size & Growth: The global antipsychotics market, of which haloperidol lactate is a part, was valued at approximately $15.5 billion in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.1% from 2023 to 2030 [1]. While haloperidol lactate itself represents a segment of this larger market, its growth is more subdued compared to newer, branded antipsychotics with different delivery mechanisms or improved side-effect profiles. The demand is sustained by its established efficacy and cost-effectiveness, particularly in public healthcare systems and for acute intervention [2].

Key Market Drivers:

• Prevalence of Mental Health Disorders: Increasing incidence of schizophrenia, bipolar disorder, and other psychotic conditions.
• Acute Agitation Management: Haloperidol lactate’s rapid onset of action makes it a go-to for managing severe agitation in emergency and inpatient settings.
• Cost-Effectiveness: As a generic drug, it offers a lower cost alternative to newer agents, making it accessible in resource-constrained environments.
• Established Treatment Guidelines: Its inclusion in various clinical guidelines for acute psychosis management ensures continued use.

Market Restraints:

• Side Effect Profile: Potential for extrapyramidal symptoms (EPS), QTc prolongation, and sedation can limit its use in certain patient populations or for long-term maintenance therapy.
• Availability of Newer Agents: Development of atypical antipsychotics with generally better tolerability profiles and diverse formulations (e.g., long-acting injectables) has led to some displacement.
• Generic Competition: Intense price competition among generic manufacturers suppresses profit margins.
• Lack of Innovation: Haloperidol lactate is an old drug with no significant patent protection for new indications or formulations, limiting opportunities for significant market share growth through innovation.

What is the Patent and Regulatory Status of Haloperidol Lactate?

Haloperidol, the active pharmaceutical ingredient in haloperidol lactate, was first patented in the late 1950s. Consequently, all original composition of matter patents have long expired.

Patent Expirations:

• Original Composition of Matter Patents: Expired in the 1970s and 1980s.
• Formulation Patents: Any patents related to specific salt forms (like lactate) or delivery methods would also have expired or be on the verge of expiration, given the drug’s age. Generic manufacturers have been able to produce and market haloperidol lactate for decades.
• New Use or Method of Treatment Patents: While theoretically possible to obtain patents for novel uses or treatment methods, there is no significant active patent litigation or assertion surrounding new indications for haloperidol lactate. The focus of innovation in antipsychotics has shifted to newer drug classes.

Regulatory Landscape: Haloperidol lactate is approved by major regulatory bodies worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). It is available as an injection for intramuscular (IM) and intravenous (IV) administration.

• FDA Approval: Approved for the treatment of schizophrenia and for the control of agitation.
• EMA Approval: Similar indications for the management of acute psychosis and agitation.
• Generic Approvals: Numerous Abbreviated New Drug Applications (ANDAs) have been approved for generic versions of haloperidol lactate injection.

Key Regulatory Considerations for Investors:

• ANDA Approvals: The existence of multiple ANDA approvals signifies a highly competitive generic market with established regulatory pathways.
• Post-Marketing Surveillance: Like all approved drugs, haloperidol lactate is subject to ongoing pharmacovigilance and potential post-marketing requirements related to its safety profile.
• Manufacturing Standards: Generic manufacturers must adhere to Good Manufacturing Practices (GMP) to maintain regulatory compliance. Any significant issues in manufacturing quality could lead to supply disruptions and regulatory action.

What are the Fundamentals of Haloperidol Lactate as a Product?

Haloperidol lactate is a first-generation (typical) antipsychotic belonging to the butyrophenone class. It is a dopamine D2 receptor antagonist.

Mechanism of Action: Haloperidol primarily blocks dopamine D2 receptors in the mesolimbic pathway of the brain. This action is believed to be responsible for its antipsychotic effects, particularly in reducing positive symptoms of psychosis such as hallucinations and delusions. Its antagonism of D2 receptors in other dopaminergic pathways (nigrostriatal, tuberoinfundibular) contributes to its side effect profile, including EPS and hyperprolactinemia.

Pharmacokinetics (Injection):

• Absorption: Rapidly absorbed after IM injection. Bioavailability is approximately 60-75% [3].
• Distribution: Widely distributed throughout the body, with significant accumulation in tissues. It is highly lipophilic.
• Metabolism: Extensively metabolized in the liver via glucuronidation and oxidative pathways.
• Excretion: Primarily excreted in urine and feces.
• Half-life: The elimination half-life is approximately 14-24 hours [3]. This allows for once or twice daily dosing in certain contexts, though acute injection implies rapid effect rather than sustained release via this formulation.

Therapeutic Indications:

• Schizophrenia: Management of psychotic symptoms.
• Acute Agitation: Rapid tranquilization in patients experiencing severe behavioral disturbances associated with psychosis, mania, or delirium.
• Tourette's Syndrome: Control of motor and vocal tics (though often reserved due to side effects).

Strengths:

• Rapid Onset of Action: Particularly important for acute agitation management.
• Efficacy: Proven effectiveness in treating positive symptoms of psychosis.
• Cost: Low cost due to generic availability.

Weaknesses:

• Side Effect Profile: High incidence of EPS (dystonia, akathisia, parkinsonism), tardive dyskinesia (TD), sedation, and anticholinergic effects.
• QTc Prolongation: Risk of cardiac arrhythmias.
• Limited Efficacy on Negative Symptoms: Less effective for negative symptoms of schizophrenia (e.g., apathy, social withdrawal) compared to some newer agents.

Formulations:

• Injectable Solution: Available in various concentrations (e.g., 5 mg/mL) for IM or slow IV administration.
• Oral Tablets & Concentrated Oral Solution: Also available, but the investment analysis focuses on the injectable formulation due to its distinct market niche for acute intervention.

What is the Competitive Landscape for Haloperidol Lactate?

The competitive landscape for haloperidol lactate is characterized by intense generic competition and indirect competition from newer antipsychotic classes.

Direct Competitors (Generic Haloperidol Lactate): Numerous pharmaceutical companies produce generic haloperidol lactate injection. This includes large generic manufacturers and smaller regional players. Price is the primary differentiator. Market share is fragmented.

Indirect Competitors (Other Acute Agitation Treatments): This is where the primary competitive pressure lies for significant market share gains or differentiation.

• Other Typical Antipsychotics (Injectable):
  • Haloperidol Decanoate (Long-Acting Injectable): While not for acute treatment, it competes for long-term maintenance and relapse prevention, offering convenience over daily oral dosing.
  • Chlorpromazine (IM): An older phenothiazine, also used for acute agitation but with a different side-effect profile.
• Atypical Antipsychotics (Injectable):
  • Olanzapine (IM/IM LA): Rapid-acting IM formulation is a common alternative for acute agitation. Long-acting injectable (LAI) offers extended treatment.
  • Ziprasidone (IM): Another IM option for acute agitation, with a potentially lower risk of EPS compared to haloperidol.
  • Aripiprazole (IM/IM LA): LAI formulations are widely used for maintenance.
  • Risperidone (IM LA): LAI option for maintenance.
  • Paliperidone (IM LA): LAI option for maintenance.
  • Brexpiprazole (LAI): Newer LAI option.

Benzodiazepines:

• Lorazepam (IM/IV): Commonly used, often in combination with antipsychotics, for rapid sedation and anxiolysis in acute agitation. Can be used as monotherapy for agitation not primarily driven by psychosis.

Comparative Analysis of Injectable Options for Acute Agitation:

Drug	Class	Route(s)	Onset of Action	Typical Side Effects	Key Differentiator
Haloperidol Lactate	Typical Antipsychotic	IM, slow IV	Rapid	EPS, Sedation, QTc prolongation	Cost-effectiveness, long history of use
Olanzapine (IM)	Atypical Antipsychotic	IM	Rapid	Sedation, Weight gain, EPS (less than haloperidol)	Potentially lower EPS risk, comparable efficacy for agitation
Ziprasidone (IM)	Atypical Antipsychotic	IM	Rapid	Sedation, EPS (generally lower than haloperidol)	Lower risk of QTc prolongation compared to haloperidol, potential for less sedation
Lorazepam	Benzodiazepine	IM, IV	Very Rapid	Sedation, Dizziness, Respiratory depression	Primarily anxiolytic and sedative, can be used alone or in combination

Investment Implications: The competitive landscape suggests that investment in the manufacturing or distribution of haloperidol lactate is a play on stable, albeit low-growth, demand for a cost-effective acute care solution. Companies focused on high-volume generic production are best positioned. Competition from atypicals and benzodiazepines limits opportunities for significant revenue growth, but also highlights haloperidol lactate's enduring role due to its cost and rapid effect profile in specific clinical scenarios.

What are the Key Investment Considerations for Haloperidol Lactate?

Investing in haloperidol lactate is akin to investing in a mature, commodity-like pharmaceutical product. The primary focus is on operational efficiency and market access rather than innovation or patent exclusivity.

1. Generic Manufacturing & Supply Chain:

• Cost of Goods Sold (COGS): Efficient manufacturing processes and sourcing of raw materials are critical to maintaining profitability given intense price competition.
• Supply Chain Reliability: Ensuring uninterrupted supply is paramount. Any disruption can lead to loss of market share to competitors, especially in hospital settings where stock-outs are unacceptable.
• Economies of Scale: Larger manufacturers with significant production volumes can achieve lower per-unit costs, providing a competitive advantage.

2. Market Access & Distribution:

• Hospital & Pharmacy Contracts: Securing contracts with major hospital networks, group purchasing organizations (GPOs), and retail pharmacy chains is essential for market penetration.
• Reimbursement: While generics are subject to price negotiations, understanding reimbursement policies and potential changes is important. Government payers (e.g., Medicare, Medicaid) and private insurers influence pricing and formulary placement.
• Global Reach: Expanding distribution to emerging markets where cost-effectiveness is a primary driver can offer growth opportunities.

3. Regulatory Compliance & Quality Control:

• Good Manufacturing Practices (GMP): Strict adherence to GMP is non-negotiable. FDA or EMA warning letters, import alerts, or product recalls can severely impact operations and reputation.
• ANDA Filings: For companies looking to enter the market, a robust ANDA filing strategy is necessary.
• Safety Monitoring: Ongoing pharmacovigilance and adverse event reporting are standard regulatory requirements.

4. Financial Metrics & Valuation:

• Profit Margins: Expect thin profit margins due to price erosion from generic competition. Profitability will largely be driven by volume.
• Revenue Stability: Revenue is likely to be stable but not high-growth. Demand is driven by prevalence of conditions requiring acute management, which has a relatively inelastic component.
• Capital Expenditure: Investment may be required for plant upgrades to maintain efficiency and compliance, but significant R&D investment for new product development is unlikely for this specific molecule.
• Valuation Multiples: Valuation will likely be based on earnings multiples, with a focus on predictable cash flows rather than high growth potential.

5. Risk Factors:

• Price Wars: Intense competition can lead to aggressive price cuts, eroding profitability.
• Regulatory Scrutiny: Increased regulatory oversight on generic drug manufacturing can lead to unexpected costs or disruptions.
• Emergence of Superior Alternatives: While haloperidol lactate is established, the continuous development of newer, potentially better-tolerated, or more convenient antipsychotics could gradually reduce its market share over the long term, though its role in acute, cost-sensitive settings is likely to persist.
• Litigation: While less common for old generics, patent challenges or product liability suits, though rare for this drug, remain a theoretical risk.

Investment Scenario: An investment in haloperidol lactate is best suited for a diversified portfolio focused on established generic pharmaceutical assets with stable demand. Companies that excel in lean manufacturing, efficient supply chain management, and broad market access are most likely to succeed. It is not an investment for those seeking high-growth, innovation-driven returns. The investment thesis is built on volume, operational excellence, and maintaining a competitive cost structure.

Key Takeaways

Haloperidol lactate is a mature generic antipsychotic drug with stable demand driven by its efficacy and cost-effectiveness in managing acute agitation and psychosis. The market is characterized by intense generic competition, leading to thin profit margins that necessitate operational efficiency and robust supply chain management for profitability. While it faces competition from newer atypical antipsychotics and benzodiazepines, its established role in acute care settings, particularly in cost-sensitive environments, ensures its continued market relevance. Investment considerations center on manufacturing expertise, regulatory compliance, and effective market access rather than product innovation.

Frequently Asked Questions

1. What is the primary clinical advantage of haloperidol lactate over newer antipsychotics for acute agitation? Haloperidol lactate's primary advantage is its rapid onset of action when administered intramuscularly and its significantly lower cost compared to newer, branded injectable antipsychotics. This makes it a preferred choice in emergency departments and psychiatric inpatient settings where immediate control of severe agitation is critical and cost is a major consideration.

2. Are there any opportunities for patentable innovation with haloperidol lactate? Given that the original composition of matter patents expired decades ago, opportunities for significant patentable innovation are extremely limited. Potential areas could include novel drug delivery systems (e.g., long-acting formulations, though this is unlikely given the drug's age and limited market interest for such development), unique combination therapies that are patentable, or entirely new therapeutic indications supported by extensive clinical trials. However, such developments are improbable for a drug of this maturity.

3. What are the major risks associated with manufacturing haloperidol lactate? The major risks include intense price competition leading to margin compression, potential supply chain disruptions due to raw material sourcing or manufacturing issues, increased regulatory scrutiny on generic drug manufacturing quality (e.g., FDA inspections, warning letters), and the slow but steady erosion of market share to newer agents that may offer improved tolerability or patient convenience for specific indications.

4. How does the global regulatory environment impact haloperidol lactate manufacturers? Manufacturers must adhere to stringent Good Manufacturing Practices (GMP) mandated by regulatory bodies like the FDA and EMA. Non-compliance can lead to import alerts, product recalls, or manufacturing shutdowns, causing significant financial and reputational damage. Maintaining regulatory approval in multiple jurisdictions is crucial for market access, but also incurs ongoing compliance costs.

5. What is the outlook for demand for haloperidol lactate in the next five to ten years? The demand for haloperidol lactate is expected to remain stable, driven by the persistent prevalence of acute agitation and psychosis in psychiatric and emergency settings, especially where cost is a primary factor. While newer agents may capture specific market segments, haloperidol lactate’s established efficacy, rapid action, and low cost ensure its continued use as a first-line or alternative treatment option in many clinical scenarios globally. Significant growth is unlikely, but a substantial decline is also not anticipated in the medium term.

Citations

[1] Grand View Research. (2023). Antipsychotics Market Size, Share & Trends Analysis Report By Drug Class (Atypical, Typical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2023 - 2030. [2] Lally, N., et al. (2023). Antipsychotic medications in schizophrenia: an overview of clinical pharmacology. British Journal of Clinical Pharmacology, 89(3), 1050-1063. [3] DrugBank. (2023). Haloperidol. Retrieved from https://go.drugbank.com/drugs/DB00726